ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits-Reference-Cited by-同舟云学术

ChREBP is activated by reductive stress and mediates GCKR-associated metabolic traits

Published:2024-01 Issue:1 Volume:36 Page:144-158.e7
ISSN:1550-4131
Container-title:Cell Metabolism
language:en
Short-container-title:Cell Metabolism

Author:

Singh Charandeep,Jin Byungchang,Shrestha Nirajan,Markhard Andrew L.,Panda Apekshya,Calvo Sarah E.,Deik Amy,Pan Xingxiu,Zuckerman Austin L.,Ben Saad Amel,Corey Kathleen E.,Sjoquist Julia,Osganian Stephanie,AminiTabrizi Roya,Rhee Eugene P.,Shah Hardik,Goldberger Olga,Mullen Alan C.,Cracan Valentin,Clish Clary B.,Mootha Vamsi K.,Goodman Russell P.^ORCID

Funder

Burroughs Wellcome Fund

American Association for the Study of Liver Diseases

J. Willard and Alice S. Marriott Foundation

National Institutes of Health

Howard Hughes Medical Institute

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Physiology

Reference78 articles.

1. Hepatic NADH reductive stress underlies common variation in metabolic traits;Goodman;Nature,2020

2. A protein from rat liver confers to glucokinase the property of being antagonistically regulated by fructose 6-phosphate and fructose 1-phosphate;van Schaftingen;Eur. J. Biochem.,1989

3. Molecular targeting of the GK-GKRP pathway in diabetes;Hale;Expert Opin. Ther. Targets,2015

4. Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels;Saxena;Science,2007

5. The P446L variant in GCKR associated with fasting plasma glucose and triglyceride levels exerts its effect through increased glucokinase activity in liver;Beer;Hum. Mol. Genet.,2009

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Do iron homeostasis biomarkers mediate the associations of liability to type 2 diabetes and glycemic traits in liver steatosis and cirrhosis: a two-step Mendelian randomization study;BMC Medicine;2024-06-26

2. Proteome-wide Mendelian randomization identifies potential therapeutic targets for nonalcoholic fatty liver diseases;Scientific Reports;2024-05-23